Literature DB >> 18005961

Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation.

Sebastian E Baumeister1, Henry Völzke, Paul Marschall, Ulrich John, Carsten-Oliver Schmidt, Steffen Flessa, Dietrich Alte.   

Abstract

BACKGROUND & AIMS: Fatty liver disease is a common condition in the Western world. Fatty liver may progress to steatohepatitis and cirrhosis. It is not yet known whether fatty liver disease results in higher health care utilization and costs.
METHODS: We used data from the Study of Health in Pomerania (SHIP), Germany, to assess the relation of fatty liver disease to self-reported health care utilization and costs at baseline and 5 years. The SHIP is a general population cohort study of 4310 adults aged 20 to 79 years at baseline in Pomerania. Fatty liver disease was defined as the presence of a hyperechogenic pattern of the liver and elevated serum alanine aminotransferase (ALT) levels.
RESULTS: In multivariable analyses, average annual overall health care costs at baseline and follow-up measurement were significantly higher for individuals with sonographic fatty liver and increased serum ALT levels. For example, controlling for comorbid conditions, subjects with sonographic fatty liver disease and increased serum ALT levels had 26% higher overall health care costs at 5-year follow-up. Analyses also suggest that diabetes and cardiovascular disease might mediate the relation of fatty liver disease and health care utilization and costs.
CONCLUSIONS: Policies seeking to minimize costs associated with fatty liver disease might want to consider addressing behavioral risk factors of fatty liver disease.

Entities:  

Mesh:

Year:  2007        PMID: 18005961     DOI: 10.1053/j.gastro.2007.10.024

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  59 in total

Review 1.  Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Melanie D Beaton
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

Review 2.  Current and Future Burden of Chronic Nonmalignant Liver Disease.

Authors:  Prowpanga Udompap; Donghee Kim; W Ray Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-17       Impact factor: 11.382

Review 3.  Nutrition and nonalcoholic fatty liver disease in children.

Authors:  Miriam B Vos; Craig J McClain
Journal:  Curr Gastroenterol Rep       Date:  2008-06

4.  Nutrition and nonalcoholic fatty liver disease in children.

Authors:  Miriam B Vos; Craig J McClain
Journal:  Curr Diab Rep       Date:  2008-10       Impact factor: 4.810

5.  Quantitative chemical shift-encoded MRI is an accurate method to quantify hepatic steatosis.

Authors:  Jens-Peter Kühn; Diego Hernando; Birger Mensel; Paul C Krüger; Till Ittermann; Julia Mayerle; Norbert Hosten; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2013-10-10       Impact factor: 4.813

6.  Do Genetic Markers of Inflammation Modify the Relationship between Periodontitis and Nonalcoholic Fatty Liver Disease? Findings from the SHIP Study.

Authors:  A A Akinkugbe; C L Avery; A S Barritt; S R Cole; M Lerch; J Mayerle; S Offenbacher; A Petersmann; M Nauck; H Völzke; G D Slade; G Heiss; T Kocher; B Holtfreter
Journal:  J Dent Res       Date:  2017-07-21       Impact factor: 6.116

7.  Periodontitis and Non-alcoholic Fatty Liver Disease, a population-based cohort investigation in the Study of Health in Pomerania.

Authors:  Aderonke A Akinkugbe; Gary D Slade; A Sidney Barritt; Stephen R Cole; Steven Offenbacher; Astrid Petersmann; Thomas Kocher; Markus M Lerch; Julia Mayerle; Henry Völzke; Gerardo Heiss; Birte Holtfreter
Journal:  J Clin Periodontol       Date:  2017-09-22       Impact factor: 8.728

8.  Ultrasound Diagnosis of Hepatic Steatosis as a Surrogate for Atherosclerosis.

Authors:  S Guth; E Windler; U Leise; C M Bamberger
Journal:  Ultrasound Int Open       Date:  2016-03-01

9.  Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

Authors:  Shira Zelber-Sagi; Muriel Webb; Nimer Assy; Laurie Blendis; Hanny Yeshua; Moshe Leshno; Vlad Ratziu; Zamir Halpern; Ran Oren; Erwin Santo
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 10.  [Liver fibrosis - pathogenesis and novel therapeutic approaches].

Authors:  F Tacke; R Weiskirchen
Journal:  Internist (Berl)       Date:  2010-01       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.